Drug factory · FDA FEI 1310298

Curia New York, Inc.

33 Riverside Avenue, Rensselaer, NY, United States

United States: 1

Serious problems, FDA action at FDA's last inspection, Feb 5, 2026.

Official Action Indicated: inspectors found significant problems and FDA recommended regulatory action, such as a warning letter or import alert.

8 drug inspections on record since 2010: 1 with no problems, 6 with problems fixed voluntarily, 1 with FDA action.

What it does, for whom

DrugRoleForNDC
BelinostatMakes the active ingredient and tests it Acrotech Biopharma Inc 72893-002
BrigatinibMakes the active ingredient and tests it Takeda Pharmaceuticals America, Inc. 63020-090, 63020-113, 63020-180 +1
DuvelisibMakes the active ingredient and tests it Secura Bio, Inc., Verastem, Inc. 73116-215, 73116-225, 71779-115 +1
LisdexamfetamineMakes the active ingredient and tests it Takeda Pharmaceuticals America, Inc. 59417-101, 59417-102, 59417-103 +10
Nitrite Ion and Thiosulfate IonMakes the active ingredient Hope Pharmaceuticals 60267-812
PrimaquineMakes the active ingredient and tests it Sanofi-Aventis U.S. LLC 0024-1596
Thiosulfate IonMakes the active ingredient Hope Pharmaceuticals 60267-705

FDA inspection history

EndedResultProgramProblems noted
Feb 5, 2026Serious problems, FDA actionDrug Quality Assurance—
Nov 1, 2023Problems found, fixed voluntarilyDrug Quality Assurance—
Nov 9, 2017Problems found, fixed voluntarilyDrug Quality Assurance—
May 22, 2015Problems found, fixed voluntarilyDrug Quality Assurance—
Jan 15, 2014Problems found, fixed voluntarilyDrug Quality Assurance—
Jan 30, 2013Problems found, fixed voluntarilyDrug Quality Assurance—
Mar 29, 2012No problems foundDrug Quality Assurance—
Apr 7, 2010Problems found, fixed voluntarilyDrug Quality Assurance—

Registered with FDA for: analysis; api manufacture; particle size reduction.